Project

A multicenter, randomized, double-blind, parallel-group,placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312)in patients with secondary progressive multiple sclerosis

Completed ยท 2014 until 2016

RSS